168 related articles for article (PubMed ID: 15801325)
1. A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator.
Colice GL; Carnathan B; Sung J; Paramore LC
J Asthma; 2005 Feb; 42(1):29-34. PubMed ID: 15801325
[TBL] [Abstract][Full Text] [Related]
2. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
Drescher GS; Carnathan BJ; Imus S; Colice GL
Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
[TBL] [Abstract][Full Text] [Related]
3. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI.
Sutherland ER; Brazinsky S; Feldman G; McGinty J; Tomlinson L; Denis-Mize K
Curr Med Res Opin; 2009 Mar; 25(3):653-61. PubMed ID: 19232039
[TBL] [Abstract][Full Text] [Related]
4. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
Hogan TJ; Geddes R; Gonzalez ER
Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
[TBL] [Abstract][Full Text] [Related]
5. Equivalence of a single saline nebulised dose of formoterol powder vs three doses of nebulised Albuterol every twenty minutes in acute asthma in children: a suitable cost effective approach for developing nations.
Rodriguez E; Vera V; Perez-Puigbo A; Capriles-Hulett A; Ferro S; Manrique J; Abate J
Allergol Immunopathol (Madr); 2008; 36(4):196-200. PubMed ID: 18928685
[TBL] [Abstract][Full Text] [Related]
6. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of nebulized levalbuterol in stable COPD.
Datta D; Vitale A; Lahiri B; ZuWallack R
Chest; 2003 Sep; 124(3):844-9. PubMed ID: 12970007
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations.
Woods JA; Usery JB; Self TH; Finch CK
South Med J; 2011 Nov; 104(11):742-5. PubMed ID: 22024782
[TBL] [Abstract][Full Text] [Related]
9. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
[TBL] [Abstract][Full Text] [Related]
10. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.
Miller E; Sears MR; McIvor A; Liovas A
Can Respir J; 2007; 14(5):269-75. PubMed ID: 17703241
[TBL] [Abstract][Full Text] [Related]
11. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
Bollu V; Ernst FR; Karafilidis J; Rajagopalan K; Robinson SB; Braman SS
Int J Chron Obstruct Pulmon Dis; 2013; 8():631-9. PubMed ID: 24353413
[TBL] [Abstract][Full Text] [Related]
12. Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease.
Prenner BM
Expert Opin Pharmacother; 2007 Dec; 8(17):3069-84. PubMed ID: 18001266
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
[TBL] [Abstract][Full Text] [Related]
14. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
15. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.
Miller E; FitzGerald JM
Can J Clin Pharmacol; 2008; 15(2):e165-76. PubMed ID: 18515918
[TBL] [Abstract][Full Text] [Related]
16. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
17. Inhaled therapy for acute COPD exacerbation in the hospital: are we missing the low-hanging fruit?
Patel DC; Ashton RW
South Med J; 2011 Nov; 104(11):746. PubMed ID: 22024783
[No Abstract] [Full Text] [Related]
18. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.
Cramer JA; Bradley-Kennedy C; Scalera A
Can Respir J; 2007; 14(1):25-9. PubMed ID: 17315055
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma.
Brunetti L; Poiani G; Dhanaliwala F; Poppiti K; Kang H; Suh DC
Am J Health Syst Pharm; 2015 Jun; 72(12):1026-35. PubMed ID: 26025994
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
Löfdahl CG; Ericsson A; Svensson K; Andreasson E
Pharmacoeconomics; 2005; 23(4):365-75. PubMed ID: 15853436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
